Vaccine for respiratory syncytial virus protection in adults
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests a new vaccine designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. The vaccine is given as a shot, and the study will check how your immune system responds to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 20 years old.
- You must be generally healthy, with no recent RSV infection or cold-like symptoms.
- No history of severe allergic reactions to any vaccine ingredients.
- No weakened immune system, autoimmune disease, or cancer (except certain cured cases).
- If you can become pregnant, you must use effective birth control during the study and for 12 months after.
- You cannot have received an RSV vaccine before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This study tests a new vaccine that may protect babies from a common breathing virus called RSV. It is given to healthy women to see if it is safe and if it helps the body make protection that could be passed to a baby during pregnancy.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.